U.S. pharmacologist Pfizer released Wednesday against the third dose of its vaccine COVID-19 According to the initial data from one study, it could “strongly increase” protection against the delta type of corona virus against the two-dose schedule.
The company pointed out in a presentation that its data suggest that it is producing a third dose Five times higher levels of antibodies against delta variation Doses after the second dose were 11 times higher in 18- to 55-year-olds and 65-to-85-year-olds in comparison.
According to a document used by the company in a conference call to discuss quarterly financial results, Pfizer calculates that the neutrality of the delta variance can be increased by 100 compared to the two-dose schedule.
As explained by the conference executives, Pfizer believes “May be required Third booster dose Maintain high levels of protection between 6 and 12 months after full vaccination “ Against Covit-19, they commented that the delta was a variant “Very spread” Saw so far.
This study is in development and has not been subjected to peer review. The third dose given at least half a year after the second is well tolerated and produces high levels of antibodies against the original corona virus and beta variant.
Pfizer said it would like to apply for US Food and Drug Administration (FDA) approval earlier this month to deliver the third dose of the corona virus vaccine developed with the German company BioNTech.
“Companies hope to publish more concise data in the analysis and all the data collected will be there Shared as part of discussions with the FDA and EMA (European Pharmaceuticals Company) and other regulators in the coming weeks ”, The pharmacist noted in a note.
On the other hand, Pfizer CEO Albert Powerla told CNBC that the company had prepared a study showing that the effectiveness of two doses of the corona virus vaccine dropped to 84% after four to six months. Management
Specific, Its maximum efficiency is 96.2%., A point that decreases by an average of 6% every two months between the first week and two months of receiving the vaccine, the study points out, which has not yet been reviewed and 44,000 people in the United States and other countries participated in it.
Powerla noted though The vaccine initially protects against hospitalization 100% corona virus, that percentage drops to 90% after six months Has a complete guide.
You may be interested in:
Follow us on Twitter …
“Passionate coffee fanatic. Social media lover. Twitter expert. Extreme music practitioner. Zombie junkie. Hardcore travel specialist.”